Neurona Therapeutics, a biotherapeutics company founded in UCSF technology to advance restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1/2 clinical trial to evaluate the safety and efficacy of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE).
